Showing 1901-1910 of 4063 results for "".
- How Ophthalmologists Are Changing Their Surgical Routines (Part 2)https://modernod.com/news/how-ophthalmologists-are-changing-their-surgical-routines-part-2/2477491/The global COVID-19 pandemic has closed many ophthalmology practices, while others are changing their operations in a big way. Leading ophthalmologists have shared videos with Eyewire News discussing how the pandemic is impacting their practices and what they’re doing in response.
- Vit-Buckle Society Annual Meeting Cancelledhttps://modernod.com/news/vit-buckle-society-annual-meeting-cancelled/2477432/The Board of Trustees and the Executive Committee of the Vit-Buckle Society (VBS) said that its annual meeting, originally scheduled for March 26-28 in Miami, has been officially cancelled, according to a email sent to its members on Friday. Previously, the meeting was designated as postposed.
- Aurion Announces Positive 12-Month Results from Phase 1/2 CLARA Trial of AURN001 Corneal Endothelial Cell Therapyhttps://modernod.com/news/aurion-announces-positive-12-month-results-from-phase-12-clara-trial-of-aurn001-corneal-endothelial-cell-therapy/2484196/Aurion Biotech announced positive 12-month results from its phase 1/2 CLARA clinical trial. The study evaluated the safety, efficacy, and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor)
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n
- Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase 1/2 Trial Evaluating Gene Therapy for XLRShttps://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-from-the-first-cohort-of-phase-12-trial-evaluating-gene-therapy-for-xlrs/2482257/Atsena Therapeutics announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 utilizes AAV.SPR, the company’s novel sprea
- First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine for the Treatment of Decreased VA Under Low Light Conditions Following Keratorefractive Surgeryhttps://modernod.com/news/first-patient-enrolled-in-lynx-2-phase-3-study-evaluating-phentolamine-for-the-treatment-of-decreased-va-under-low-light-conditions-following-keratorefractive-surgery/2482227/Ocuphire Pharma announced the enrollment of the first subject in the LYNX-2 phase 3 registration study evaluating phentolamine ophthalmic solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery. The LY
- Regenxbio Announces Interim Data from Phase 2 AAVIATE Trial of ABBV-RGX-314 for Wet AMD Using Suprachoroidal Deliveryhttps://modernod.com/news/regenxbio-announces-interim-data-from-phase-2-aaviate-trial-of-abbv-rgx-314-for-the-treatment-of-wet-amd-using-suprachoroidal-delivery/2482066/Regenxbio announced positive interim data from the phase 2 AAVIATE trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (AMD) using suprachoroidal delivery. Investigational ABBV-RGX-314 is designed to be a one-time, in office treatment that has the potent
- Aviceda Announces Topline Data From Part 1 of the Phase 2/3 SIGLEC Trial of GA Drug Candidate AVD-104https://modernod.com/news/aviceda-therapeutics-announces-topline-data-from-part-1-of-the-phase-23-siglec-clinical-trial-for-avd-104-demonstrating-positive-safety-and-early-clinical-efficacy-in-patients-with-geographic-atrophy/2482061/Aviceda Therapeutics announced positive topline data of part 1 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single
- Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/Azura Ophthalmics announced positive topline efficacy and safety results from a phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD). The trial met its prim
- Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase 1/2 Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-12-month-safety-and-efficacy-data-from-phase-12-trial-of-atsn-101-in-patients-with-lca1/2481991/Atsena Therapeutics announced positive 12-month safety and efficacy data from the ongoing phase 1/2 trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 ha